登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由山东省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07600268,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed diagnosis of pancreatic - adenocarcinoma.
入选标准第 2 条
Completion of first-line chemotherapy with stable disease (SD) or partial response (PR) after ≥4 months of treatment.
入选标准第 5 条
Currently participating in any interventional clinical trial or having received other investigational drugs or devices within 4 weeks prior to enrollment.
排除标准第 1 条
ECOG performance status of 0-2.
入选标准第 6 条
Hemoglobin (Hb) ≥ 90 g/L
入选标准第 9 条
Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L
入选标准第 10 条
Platelets (PLT) ≥ 75×10⁹/L
入选标准第 11 条
Total bilirubin ≤ 1.5× ULN or direct bilirubin ≤ ULN
入选标准第 12 条
ALT/AST ≤ 2.5× ULN
入选标准第 13 条
ALP ≤ 2.5× ULN
入选标准第 14 条
Serum creatinine ≤ 1.5× ULN or calculated creatinine clearance ≥ 40 mL/min
入选标准第 15 条
At least one measurable lesion of the primary pancreatic tumor as per RECIST 1.1 criteria, eligible for SBRT.
入选标准第 4 条
Active, untreated hepatitis B (HBsAg positive and detectable HBV-DNA) or active hepatitis C infection (HCV antibody positive and detectable HCV RNA).
排除标准第 5 条
Women of childbearing potential and men must use effective contraception during the study and for 12 months following treatment completion.
入选标准第 18 条
Pregnant or breastfeeding women.
排除标准第 6 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07600268,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age 18 to 70 years old. Histologically or cytologically confirmed diagnosis of pancreatic - adenocarcinoma. No prior radiation therapy for pancreatic cancer. At least one measurable lesion of the primary pancreatic tumor as per RECIST 1.1 criteria, eligible for SBRT. Completion of first-line chemotherapy with stable disease (SD) or partial response (PR) after ≥4 months of treatment. ECOG performance status of 0-2. Expected survival of ≥3 months. Adequate organ function within 14 days prior to enrollment: Hemoglobin (Hb) ≥ 90 g/L Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L Platelets (PLT) ≥ 75×10⁹/L Total bilirubin ≤ 1.5× ULN or direct bilirubin ≤ ULN ALT/AST ≤ 2.5× ULN ALP ≤ 2.5× ULN Serum creatinine ≤ 1.5× ULN or calculated creatinine clearance ≥ 40 mL/min Urine protein < 2+ (if ≥2+ on dipstick, 24-hour urine protein must be < 2g) No use of systemic corticosteroids in the last 7 days prior to enrollment (physiological corticosteroid replacement is allowed). Women of childbearing potential and men must use effective contraception during the study and for 12 months following treatment completion. Voluntary participation with signed informed consent. Ability to comply with the study schedule.排除标准:Exclusion Criteria:
Currently participating in any interventional clinical trial or having received other investigational drugs or devices within 4 weeks prior to enrollment. Peritoneal metastasis. Known active central nervous system (CNS) metastasis and/or carcinomatous meningitis. Receiving systemic corticosteroid treatment within 7 days prior to enrollment (except for physiological doses). Active, untreated hepatitis B (HBsAg positive and detectable HBV-DNA) or active hepatitis C infection (HCV antibody positive and detectable HCV RNA). Pregnant or breastfeeding women. Any severe or uncontrolled systemic disease, including: QTc interval ≥ 480 ms Unstable angina NYHA class III-IV congestive heart failure Arterial thromboembolism (MI, unstable angina, stroke, TIA) within 6 months prior to enrollment Uncontrolled hypertension (systolic BP ≥ 150 mmHg, diastolic BP ≥ 90 mmHg) Active pulmonary tuberculosis, severe infections, or other uncontrolled diseases Active gastrointestinal perforation, fistula, or bowel obstruction. Inadequately controlled diabetes (fasting blood glucose > 10 mmol/L). History of mental illness preventing compliance with treatment. Active bleeding or significant coagulation abnormalities within the last 30 days. Previous gastrointestinal perforation or other serious gastrointestinal conditions in the past 6 months. Participation in other trials that may interfere with this study.
引自 ClinicalTrials.gov, NCT07600268, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07600268,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。